Korro Bio (KRRO) to Release Earnings on Tuesday

Korro Bio (NASDAQ:KRRO) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Korro Bio to post earnings of ($1.93) per share and revenue of $0.4250 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 18, 2026 at 9:30 AM ET.

Korro Bio Price Performance

Shares of KRRO stock opened at $12.30 on Tuesday. The firm has a market cap of $115.87 million, a PE ratio of -1.31 and a beta of 2.98. Korro Bio has a 1-year low of $5.20 and a 1-year high of $55.89. The company has a 50-day moving average of $10.68 and a two-hundred day moving average of $20.41.

Wall Street Analysts Forecast Growth

KRRO has been the subject of several research analyst reports. Piper Sandler cut shares of Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 target price for the company. in a report on Thursday, November 13th. Wall Street Zen cut Korro Bio from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Thursday, January 29th. JonesTrading lowered Korro Bio from a “buy” rating to a “hold” rating in a research note on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $50.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new position in Korro Bio during the fourth quarter valued at approximately $4,806,000. TCG Crossover Management LLC bought a new position in Korro Bio during the third quarter worth $19,937,000. Vanguard Group Inc. grew its position in Korro Bio by 2.3% during the third quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock worth $18,948,000 after buying an additional 8,921 shares in the last quarter. Polar Capital Holdings Plc increased its position in shares of Korro Bio by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock valued at $12,676,000 after purchasing an additional 14,694 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Korro Bio by 1.8% in the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after buying an additional 4,650 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.